DDIT3 and diffuse large B-cell lymphoma: In addition, DE-DLBCL patients with p53 expression >50% had significantly longer PFS treated with ZR-CHOP than those treated with R-CHOP (1-year PFS rate: 100% vs. 55.6%, P= 0.0033).